<DOC>
	<DOC>NCT02356224</DOC>
	<brief_summary>SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose study the investigators evaluated the safety, tolerablity and PK/PD profiles of SHR3824 in healthy subjects.</brief_summary>
	<brief_title>The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Chinese male and female subjects aged 18 to 45 years. BMI:18 25 kg/m2 . Healthy according to medical history, physical examination findings, 12lead ECG findings, and clinical laboratory evaluations. Exclusion criteria: History of or current clinically significant medical illness as determined by the Investigator. History of clinically significant allergies, especially known hypersensitivity or intolerance to lactose. Pregnancy or breastfeeding . Significant acute or chronic medical illness, including renal impairment, or recent surgery. Donation of blood or plasma within the 4 weeks prior to the start of the study or acception of blood transfusion within 8 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
</DOC>